Actualización general de inmunoterapia en cáncer / Cancer immunotherapy: an update
Rev. méd. Chile
;
148(7): 970-982, jul. 2020. tab
Artículo
en Español
| LILACS
| ID: biblio-1139399
ABSTRACT
Cancer is one of the leading causes of death worldwide. The success rate of conventional anticancer therapeutic approaches such as chemotherapy is limited by the non-specific toxicity and low specificity towards specific tumors, which are highly dependent on the mutational burden present on each patient. Similarly, targeted therapies have proven to induce resistance in numerous malignancies. Therefore, immunotherapy has emerged as a better approach to discriminate between "the own" and "the non-own", which occurs through two types of mechanisms, innate and acquired immunity. Acquired immunity is one of the targets for new immunotherapeutic treatments, unleashing the power of antigen-specific T cells as a potential therapeutic weapon for cancer treatment. Thus, immunotherapy modifies the own immune system to increase the recognition and elimination of cancer cells by identifying these cancer antigens. One of the advantages of immunotherapy, when compared to conventional anticancer approaches, is the generation of long-term immunity (immunological memory). Currently, there are different potential types of immunotherapy in cancer to promote the modulation of the immune response. Among them, the use of cytokines, vaccines, viruses, monoclonal antibodies, and the generation of adaptive immune response cells have achieved successful results in some types of cancer.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Inmunoterapia
/
Neoplasias
Límite:
Humanos
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Chile
/
Estados Unidos
Institución/País de afiliación:
Cáncer Fundación Arturo López Pérez/CL
/
Dirección Servicio de Salud Concepción/CL
/
George Washington Cancer Center/US
/
Universidad Católica de la Santísima Concepción/CL
Similares
MEDLINE
...
LILACS
LIS